Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2023-08-28 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2023. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the half-year period. It also includes business descriptions, shareholder information, and notes on asset pledges. The document length is over 5,000 characters and contains substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-28 Chinese
2023年半年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2023 年半年度权益分派预案公告" which translates to "2023 Half-Year Dividend Distribution Plan Announcement." It discusses the company's proposed dividend distribution plan based on the 2023 half-year financial report (unaudited). The document includes details about the dividend amount, board and supervisory committee approvals, independent director opinions, and references to company bylaws regarding profit distribution. It also mentions that the plan will be submitted to the shareholders' meeting for approval. The document length is 3318 characters, which is relatively short and primarily serves as an announcement of the dividend distribution plan rather than a full financial report or detailed interim report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related details for shareholders.
2023-08-28 Chinese
使用闲置募集资金购买理财产品公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the use of idle raised funds to purchase financial products. It details the amount of funds raised through a public offering, the usage and storage of these funds, the decision-making process for investing idle funds in low-risk financial products, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document is focused on capital usage and financing activities related to the company's fundraising proceeds. It is not a full financial report, earnings release, or regulatory filing, but rather an update on the company's capital management and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3074 characters, which is consistent with an announcement rather than a full report.
2023-08-28 Chinese
关于拟修订《公司章程》公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed amendments to the company's Articles of Association (公司章程). It details specific changes to share capital and registered capital following a public stock issuance and listing on the Beijing Stock Exchange. The document includes references to relevant laws and regulations and mentions that the amendments will be submitted to the shareholders' meeting for approval. The content is regulatory in nature, announcing corporate governance changes but does not contain financial statements or detailed reports. It is not a full report like an Annual Report or Interim Report, nor is it a voting result or proxy solicitation. Given the nature of the announcement about governance document amendments, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-08-28 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司使用闲置募集资金购买理财产品的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of idle raised funds by Shanxi Jinbo Biopharmaceutical Co., Ltd. to purchase financial products. It includes specifics about the fundraising, usage plans, investment decisions, risk controls, and opinions from independent directors, the supervisory board, and the sponsor institution. The document is regulatory in nature, focusing on compliance and verification of fundraising usage rather than presenting financial statements or earnings data. It does not contain financial results, earnings highlights, or management discussion of financial performance. It is not an announcement of a report but a formal verification opinion related to fundraising and capital use. This fits best under Regulatory Filings (RNS), which covers compliance documents and miscellaneous filings that do not fit other categories.
2023-08-28 Chinese
独立董事关于公司第三届董事会第二十四次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on several proposals related to the company's 2023 semi-annual report, dividend distribution plan, capital change, and use of idle raised funds. It references the 2023 semi-annual report and related matters but does not contain the actual financial statements or detailed financial data itself. The document is relatively short (1464 characters) and serves as an announcement of opinions on agenda items for a board meeting rather than the report itself. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as it provides regulatory compliance information and independent directors' opinions on corporate governance matters without substantive financial data.
2023-08-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.